About HK Innoen
HK Innoen is a publicly listed company based in Seoul (South Korea) founded in 1984. Drugs are manufactured by HK Innoen in South Korea. The company has 1,720 employees. Its chief executive, as recorded, is Seokhee Kang. Its website inno-n.com draws about 97 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals.
Company details
HK Innoen was established in 1984 in Seoul, South Korea, where pharmaceutical drugs are produced as the core activity. Operations are centered on drug manufacturing within the healthcare sector, with facilities located in South Korea. Leadership is provided by CEO Seokhee Kang. The companys online presence is maintained through the domain inno-n.com, supporting its focus on pharmaceutical production.
- Headquarters Seoul, South Korea
- Employees 1,720
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website inno-n.com
- Social LinkedIn YouTube
- Legal Name Hk Inno.N Corporation
- Annual Revenue$733.97 M (USD)18.5as on Dec 31, 2025
- Net Profit$52.42 M (USD)22.93as on Dec 31, 2025
- EBITDA$107.91 M (USD)20.3as on Dec 31, 2025
- Employee Count1,720
People of HK Innoen
5 people are tracked at HK Innoen (3 in leadership, 2 in team); the tracked headcount is 1,720.
| Name | Role | Group |
|---|---|---|
Seokhee Kang | CEO | Leadership |
Dalwon Kwak | CEO and President | Leadership |
Sung bin Cho | 部長, General Manager Of K-cap BD And Marketing, Head Of Japan Office | Leadership |
Ga-Young Lee | Senior Business Development Analyst | Team |
Jaewon Lee | Marketing Manager | Team |
Complete people profiles for HK Innoen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HK Innoen
HK Innoen is a publicly listed company on the KRX with ticker symbol 195940 in South Korea, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Aug 2021
- Listed onKRX: 195940
- Listed entityHK inno.N Corporation
- Exchange sectorHealth services
- ISINKR7195940002
- Share price36,000.00 KRW (-4.13% on the day) · 2026-10-14
- Market capitalisation1,063,787,414,742.00 KRW
- Price to earnings11.9
- EPS (diluted, trailing year)3,030.35 KRW
- Dividend yield1.09%
- Volume (last session)121,212
Financials of HK Innoen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1,060.00B KRW | 75.70B KRW | 155.84B KRW |
| 2024 | 897.14B KRW | 61.58B KRW | 129.54B KRW |
| 2023 | 828.91B KRW | 47.20B KRW | 101.39B KRW |
| 2022 | 846.52B KRW | 38.13B KRW | 87.11B KRW |
| 2021 | 769.79B KRW | 24.74B KRW | 82.57B KRW |
Detailed financial statements for HK Innoen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of HK Innoen
The website of HK Innoen (inno-n.com) receives about 96.6K visits a month.
- Monthly visits96.6K
▼ 21.4% vs previous month
Websites whose visitors overlap most with HK Innoen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
druginfo.co.kr | druginfo.co.kr | 100% | #78,870 | – | |
newsthevoice.com | newsthevoice.com | 99% | #553,091 | – | |
| pharmnews.com | 92% | #274,610 | View details | ||
doctorsnews.co.kr | doctorsnews.co.kr | 90% | #144,717 | – | |
mdon.co.kr | mdon.co.kr | 90% | #615,689 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for HK Innoen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hk Innoen
Complete news archive for HK Innoen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HK Innoen
HK Innoen was founded in 1984.
HK Innoen is headquartered in Seoul, South Korea.
Seokhee Kang is the CEO of HK Innoen, as recorded in our data.
HK Innoen has 1,720 employees.
Annual revenue of HK Innoen is $733.97M as on Dec 31, 2025.
HK Innoen was established in 1984 in Seoul, South Korea, where pharmaceutical drugs are produced as the core activity. Operations are centered on drug manufacturing within the healthcare sector, with facilities located in South Korea. Leadership is provided by CEO Seokhee Kang. The companys online presence is maintained through the domain inno-n.com, supporting its focus on pharmaceutical production.
Yes, HK Innoen is publicly traded on KRX under the ticker symbol 195940.